• Nippon Shinyaku faces lawsuit filed May 7, 2026 in New Jersey Superior Court, Chancery Division, Bergen County by Capricor Therapeutics seeking injunction tied to commercialization and distribution agreement for CAP-1002 (deramiocel).
• Case targets U.S. distribution rights under agreement, raising uncertainty over planned U.S. launch as CAP-1002 remains under FDA review for Duchenne muscular dystrophy cardiomyopathy.
• Capricor challenges amendments to agreement, alleges launch preparations by Nippon Shinyaku and NS Pharma are insufficient.
• Nippon Shinyaku rejects claims, signals willingness to negotiate while preparing to defend distribution rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.